GEN Exclusives

More »

GEN News Highlights

More »
Aug 26, 2014

Bio-Techne Picks Up MRC Technology's Protein Synthesis Tech

  • Tech transfer organization MRC Technology negotiated a license allowing Bio-Techne to develop reagent products using a protein synthesis technology, Genetically encoded Orthogonal Protection and Activated Ligation (GOPAL), developed at the MRC Laboratory of Molecular Biology. Bio-Techne company Boston Biochem will be applying the technology to its products and plans to test out how well it can introduce post-translational modifications into proteins for structural and functional studies.

    GOPAL, according to MRC, enables the formation of site-specific isopeptide bonds between proteins. Bio-Techne initially plans to apply GOPAL toward developing ubiquitin dimers and in the future may also use it to develop trimers and tetramers. The technology, which the firms say has already been validated for ubiquitin, may also be applied to other proteins as well. MRC believes GOPAL offers an advantage over in vitro synthesis as it allows for the production of a homogenous product via the cellular expression of ubiquitin with a protected lysine incorporated at a site-specific, user-defined site. 

    "We have every confidence that the reagents produced will be of great value to researchers," Ranmali Nawaratne, Ph.D., senior business manager at MRC Technology, said in a statement.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »